Modigraf (Tacrolimus)

Tacrolimus binds to the protein FKBP‑12 inside immune cells, forming a complex that blocks calcineurin. This inhibition stops the activation of nuclear factor‑of‑activated T‑cells, reducing the production of interleukin‑2 and other cytokines, which in turn suppresses T‑cell proliferation and the overall immune response.

The specific dose of Modigraf is individualized by the prescribing physician based on factors such as the type of transplant, patient weight, kidney function and blood tacrolimus concentrations. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for tacrolimus in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified obstetrician or transplant specialist.

To request Modigraf, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with cyclosporine, another calcineurin inhibitor, tacrolimus generally offers more potent T‑cell suppression and may require lower blood concentrations, but both share similar safety profiles. Choice of therapy depends on individual patient factors, physician experience and specific transplant protocols.

Modigraf should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and do not store in the bathroom or near a kitchen sink.

Modigraf is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact timing and frequency are tailored to maintain target blood levels and should follow the healthcare provider’s instructions.

The most serious adverse effects include nephrotoxicity (kidney damage), neurotoxicity (seizures or severe confusion), serious infections due to immune suppression, and an increased risk of certain malignancies. Patients should be monitored regularly for these complications.

Modigraf is contraindicated in patients with known hypersensitivity to tacrolimus or any of its excipients, and it should be used with caution in individuals with severe liver impairment, uncontrolled infections, or pre‑existing kidney disease. A transplant specialist should evaluate suitability before initiating therapy.